Alphatec Holdings (NASDAQ:ATEC) has announced the commercial release of its IdentiTi-PC porous Titanium Interbody Implant System. As quoted in the press release: “The commercial launch of IdentiTi-PC demonstrates continued solid progress against our commitment to accelerate growth by compelling the spine market and engaging surgeons with clinical distinction,” said Pat Miles, Chairman and Chief Executive …

Alphatec Holdings (NASDAQ:ATEC) has announced the commercial release of its IdentiTi-PC porous Titanium Interbody Implant System.

As quoted in the press release:

“The commercial launch of IdentiTi-PC demonstrates continued solid progress against our commitment to accelerate growth by compelling the spine market and engaging surgeons with clinical distinction,” said Pat Miles, Chairman and Chief Executive Officer. “This marks the fourth of twelve new product launches planned for 2019, an extraordinary level of development by any measure. We have built the spine market’s new organic innovation machine.”

TLIF IdentiTi-PC Porous Titanium Interbody Implant System

The launch of the IdentiTi-PC Interbody Implant System follows successful alpha evaluations that began in August 2018. It marks the third of six IdentiTi implant systems the Company expects to commercially introduce in 2019.

The IdentiTi line of implant systems are manufactured using a subtractive process, which begets more predictable, proprietary porosity and results in enhanced imaging characteristics. The implants are expected to perform better than competitive titanium implant offerings. The IdentiTi line of implants will not only complement the Company’s current suite of PEEK implants, but will also allow ATEC to address the broader market of surgeons who prefer titanium.

Click here to read the full press release.

Featured
IDBS, a Danaher operating company, announced Polar Insight, bringing new advanced data analytics and visualization tools to the Polar BioPharma Lifecycle Management platform. Extracting valuable insights from process and quality data across the biopharmaceutical lifecycle is a time consuming and error prone process, requiring laborious manual work and multiple steps. IDBS Polar replaces paper records, spreadsheets ...

IDBS, a Danaher (NYSE:DHR) operating company, announced Polar Insight, bringing new advanced data analytics and visualization tools to the Polar BioPharma Lifecycle Management (BPLM) platform.

Extracting valuable insights from process and quality data across the biopharmaceutical lifecycle is a time consuming and error prone process, requiring laborious manual work and multiple steps.

read more Show less
Transformative AI System Enhances Colorectal Cancer Detection Capabilities  Medtronic Canada ULC, a subsidiary of Medtronic plc — the global leader in medical technology — announced it has received a Health Canada licence for the GI Genius™ intelligent endoscopy module. GI Genius is a computer-aided detection system that uses artificial intelligence to highlight regions of the colon suspected to have visual ...

Transformative AI System Enhances Colorectal Cancer Detection Capabilities

 Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT) — the global leader in medical technology — announced it has received a Health Canada licence for the GI Genius™ intelligent endoscopy module. GI Genius is a computer-aided detection (CADe) system that uses artificial intelligence (AI) to highlight regions of the colon suspected to have visual characteristics consistent with different types of mucosal abnormalities.

read more Show less
Thermo Fisher Scientific Inc. the world leader in serving science, today confirmed that its polymerase chain reaction TaqPath COVID-19 Combo Kit *, and TaqPath COVID-19 CE-IVD RT-PCR Kit *, which test for the presence of SARS-CoV-2, are not impacted by the emerging B.1.1.529, or Omicron variant, enabling accurate test results. The Omicron variant, which was designated a " variant of concern " by the World Health ...

- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today confirmed that its polymerase chain reaction (PCR) TaqPath COVID-19 Combo Kit *, and TaqPath COVID-19 CE-IVD RT-PCR Kit *, which test for the presence of SARS-CoV-2, are not impacted by the emerging B.1.1.529, or Omicron variant, enabling accurate test results.

The Omicron variant, which was designated a " variant of concern " by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone. The WHO has reported that preliminary evidence suggests an increased risk of transmission compared to other variants of concern. This designation and information are leading to renewed travel restrictions and research to examine the variant's impact on efficacy of existing vaccines and tests. The WHO and European Centers for Disease Control have both reported that using S-gene target failure (SGTF) of the PCR assays as a proxy for the variant helped to identify Omicron. Cases of the variant were first identified in South Africa and have now been reported in at least a dozen countries around the world.

read more Show less

MARKETS

Markets
TSX20927.09+267.10
TSXV947.50+8.06
DOW34852.75+369.03
S&P 5004630.51+63.51
NASD15737.92+200.23
ASX7256.00+16.20

COMMODITIES

Commodities
Gold1787.00+13.62
Silver22.72-0.09
Copper4.280.00
Palladium1749.66+4.17
Platinum950.00+11.50
Oil67.95+1.77
Heating Oil2.12+0.06
Natural Gas4.38-0.19